If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
166
results.
Updated on
17/05/2025 [07:15:00]
Results 125 to 150 of 166
Absstract of: EP4529936A2
Embodiments of the present disclosure are directed to miniature insulin patch pump, assistance devices (e.g., for reservoir filling and /or cannula insertion), and methods related thereto. For example, in some embodiments, a substance/drug-delivery patch pump is provided and includes a reusable part (RP) including a power source, a driving mechanism, and an electronic module, and a disposable part (DP), where the disposable part can include at least a plurality of an adhesive base, a reservoir, a dosing mechanism, and a cannula.
Absstract of: EP4531051A1
Embodiments disclosed herein relate to systems and methods for adapting ambulatory infusion pump systems to operate with different types of continuous glucose monitoring (CGM) sensors. Infusion pump systems as disclosed herein can include software configured to store characteristics for different types of CGM sensors and can interface with a given type of CGM sensor based on specific characteristics and requirements of the given type of sensor.
Absstract of: CN106456063A
The present disclosure relates to a system and method for determining a basal rate adjustment based on risk associated with a glucose state of a person with diabetes. The method may include detecting a glucose state of the person based on a received glucose measurement signal and determining a current risk metric associated with the detected glucose state. The method may include identifying a reference glucose state and a reference risk metric associated with the reference glucose state, and calculating an adjustment to a basal rate of a therapy delivery device based on the current risk metric associated with the detected glucose state and the reference risk metric associated with the reference glucose level.
Absstract of: AU2023282325A1
The present disclosure provides a shielding apparatus for a lower end of an injection needle and an injection device, and relates to the technical field of injection instruments. By using the shielding apparatus for a lower end of an injection needle in the present disclosure, 5 in the process of mounting a needle holder on an insulin pen, a shielding cylinder in the needle holder moves upwardly due to a thrust given by the connection between the insulin pen and the needle holder; upon the completion of the action of mounting the needle holder on the insulin pen, the limit of the shielding cylinder in the needle holder is removed; upon the completion of a liquid medicine injection, the injection needle is taken off from the insulin 10 pen, the insulin pen is separated from the shielding cylinder, and a limit block moves downwardly along a moving groove to drive the shielding cylinder to move downwardly, so as to gradually cover the lower end of the injection needle downwardly; and when the injection needle is completely removed from the insulin pen, the limit block also moves downwardly to abut against a bottom wall of the moving groove, and the shielding cylinder 15 completely covers the lower end of the injection needle, so as to avoid a situation that a user accidentally touches the lower end of an injection needle to be injured, thereby avoiding the safety risk when the lower end of the injection needle is removed.
Absstract of: AU2023343209A1
Disclosed are techniques, devices and systems that provide adjustments to parameter settings of an insulin delivery algorithm based on inputs from a number of generic sensor devices. A majority of the generic sensor devices provide sensor readings that are unused as inputs to a drug deliver algorithm. The generic sensor devices may be operable to detect characteristics, such as changes in a state of a user. A processor may evaluate a sensor reading provided by a particular sensor with respect to a sensor baseline reading for the particular sensor. Using the result of the evaluation, the processor may calculate an adjustment to a parameter setting or settings of a medication delivery algorithm. A dosage of medication may be modified based on the adjustment of the parameter setting or settings.
Absstract of: US2025099674A1
Disclosed herein are systems and methods for transitioning between different CGM sensors in an infusion pump system with no loss in continuity of glucose levels between different sensor for use in closed loop diabetes therapy. Notifications can be provided to the user when a subsequent CGM sensor ought to be inserted, based on specific mechanics of the previous CGM sensor and of the anticipated subsequent CGM sensor. The system can further provide a notification when the subsequent CGM sensor is activated following the warm up period and capable of transmitting CGM data for use in the system and can prompt the user to or automatically transition the system from communicating with the previous sensor for CGM data to the subsequent sensor. Following the transition, the system may also notify the user that the previous CGM sensor can be removed from the user's body.
Absstract of: US2025099680A1
An insulin delivery monitoring system that includes an insulin delivery device and a controller configured to perform or control performance of operations. A method of insulin delivery includes determining a correction dose of insulin and triggering an alert.
Absstract of: US2025099679A1
Enclosed herein are methods and systems for establishing communication protocols between wireless devices in infusion pump systems. Infusion pump systems can include a number of components capable of wireless communication with one or more other components including an infusion pump, a continuous glucose monitoring (CGM) system, and a smartphone or other multi-purpose consumer electronic device (i.e., remote control device). Communications among these devices can be coordinated to ensure reliable and consistent transmission of medical data.
Absstract of: WO2025064882A2
A system includes an analyte measurement system and a software application operatively coupled to the analyte measurement system. The analyte measurement system is configured to measure a ketone level in the bodily fluid of a patient. The application is configured to display at least one of (1) a current ketone level and an indicator of a current ketone trend, (2) a ketone trend graph, and (3) a total amount of time that the ketone levels are above at least one predetermined threshold level. The application is also configured to determine if the current ketone level is above the at least one predetermined threshold level, and in response to determining that the current ketone level is above the at least one predetermined threshold level, output an alarm, wherein the alarm is outputted periodically while the current ketone level is above the at least one predetermined threshold level.
Absstract of: WO2025064603A1
A method for determining a time for obtaining laboratory glycated hemoglobin measurements can include receiving at least one glucose level for a subject during at least one time period, receiving a first measured glycated hemoglobin (HbAlc) level for the subject corresponding to a beginning of a first time period of the at least one time period, determining a first calculated glycated hemoglobin (HbAlc) level corresponding to the first time period, determining for the first time period a second calculated glycated hemoglobin (HbAlc) level using a first offset value, determining for the first time period a third calculated glycated hemoglobin (HbAlc) level using a second offset value, calculating a first difference between the first calculated glycated hemoglobin (HbAlc) level and the second calculated glycated hemoglobin (HbAlc) level, calculating a second difference between the first calculated glycated hemoglobin (HbAlc) level and the third calculated glycated hemoglobin (HbAlc) level, and generating an alert notification to obtain a second measured glycated hemoglobin (HbAlc) level for the subject in response to a determination that the first difference or the second difference is above a first predetermined threshold value.
Absstract of: WO2025060173A1
A personalized closed-loop artificial pancreas system, comprising: a measurement module (100) for continuously measuring the blood glucose level of a patient; an infusion module (102) for infusing insulin into the body of the patient; and a program module (101) for controlling the measurement module (100) and the infusion module (102). At least on the basis of the blood glucose level measured by the measurement module (100), the program module (101) generates an insulin infusion instruction, and controls the infusion module (102) to perform infusion; the program module (101) comprises a user interface; in response to the input of the patient, the program module (101) executes functions of corresponding meal patterns; the meal patterns comprise a high-carbohydrate pattern and a normal-carbohydrate pattern; and on the basis of the input of the patient, the program module (101) executes the function of the high-carbohydrate pattern or the normal-carbohydrate pattern. The present invention can be adapted to people having different carbohydrate consumption habits, improve the adaptability of a closed-loop artificial pancreas to different people, and enable people having different carbohydrate consumption habits to maintain a satisfactory blood glucose control effect.
Absstract of: WO2025060174A1
Disclosed in the present invention is a closed-loop artificial pancreas system, comprising: a measuring module, used for continuously measuring the blood glucose level of a patient; an infusion module, used for infusing insulin into the body of a patient; and a program module, used for controlling the measuring module and the infusion module, wherein at least on the basis of the blood glucose level measured by the measuring module, the program module generates an insulin infusion instruction, and controls the infusion module to perform infusion. The system uses an infusion strategy of pre-infusion and supplemental infusion, the amount of insulin for the pre-infusion is related to an estimated meal size during the pre-infusion, and the amount of insulin for the supplemental infusion is related to an estimated meal size during the supplemental infusion. There is no need to explicitly determine a meal size. On the basis of an estimated meal size, the system determines the amount of insulin to be infused. On one hand, the pressure of needing to accurately determine a meal size is reduced, and on the other hand, considering the dynamic effects of a meal and a high-dose infusion on the blood glucose level, the infusion strategy of pre-infusion and supplemental infusion is used, so that the blood glucose level of a patient is maintained at an ideal level.
Absstract of: WO2025059863A1
A control system for blood glucose monitoring and management. A first working mode of the control system is to control a blood glucose monitoring device to perform real-time blood glucose monitoring. The control system enters a second working mode on the basis of a trigger condition, and the second working mode at least comprises controlling the blood glucose monitoring device to perform real-time blood glucose monitoring and controlling an insulin infusion device to perform insulin infusion. By means of the trigger condition, the control system enters the second working mode of at least controlling the blood glucose monitoring device to perform real-time blood glucose monitoring and controlling the insulin infusion device to perform insulin infusion from the first working mode of controlling the blood glucose monitoring device to perform real-time blood glucose monitoring, so that a patient is prevented from accidentally entering unnecessary or unauthorized working modes, and the safety of blood glucose monitoring and management of the patient is improved.
Absstract of: WO2025064967A1
Disclosed herein are methods for establishing communication protocols between wireless devices in infusion pump systems. Infusion pump systems can include a number of components capable of wireless communication with one or more other components including an infusion pump, a continuous glucose monitoring (CGM) system and a smartphone or other multi-purpose consumer electronic device. Communications among these devices can be coordinated to increase efficiency and conserve battery power.
Absstract of: WO2025064557A1
Conditions of pathophysiologic dysglycemia, associated with type 1 diabetes, can be detected early, including in children. Glycemia data is collected by continuous glucose monitoring devices connected to a cloud server. The server learns person-specific patterns of glycemia and trains a model accordingly, which may serve as a baseline for comparison or as the basis for prediction of future patterns. Such models are conditioned by risk factors and various concurrent activities such as exercise and consumption of sugars. Person-specific models trained at different time periods give different simulated patterns of glycemia. Deviations between the simulated patterns, or between the predicted and actual patterns, can indicate progression of pathophysiologic dysglycemia and type 1 diabetes. These models and comparisons can be further interpreted by the software to result in a reported recommendation for additional diagnostic testing or a reported conclusion of diagnosis and recommendation of preventative intervention.
Absstract of: WO2025064417A1
Embodiments can relate to an insulin delivery controller which implements a processor configuration to efficiently attain an insulin delivery target. The insulin delivery controller can include a processor and a memory associated with the processor. The processor can process glucose data received from the memory, including a data representation of glycemic disturbance (d(t)). The processor can determine a glucose rate of change (G'(t)). The processor can generate a command signal to dynamically reshape a glycemic disturbance within a prediction horizon of the insulin delivery controller according to the G'(t). The processor can generate an insulin command signal for an insulin delivery unit to adjust an insulin delivery dosage amount and/or an insulin delivery dosage rate.
Absstract of: US2025099593A1
According to the invention there is provided inter alia an aqueous liquid pharmaceutical formulation comprising insulin or an insulin analogue, ionic zinc, a chelating agent and polysorbate 80.
Absstract of: US2025098989A1
Provided is a continuous blood glucose monitoring system, including a container shell, and a spring, a continuous blood glucose detection apparatus and a trigger structure which are arranged inside the container shell. One end of the spring is connected to an interior of the container shell, and the other end of the spring is connected to the continuous blood glucose detection apparatus. The trigger structure is arranged on a side edge of the interior of the container shell, a protruding portion is arranged on the trigger structure, which is unlockably locked with the continuous blood glucose detection apparatus. The continuous blood glucose detection apparatus includes: an apparatus shell and a circuit board arranged in the apparatus shell; a probe assembly being connected to the circuit board; and a pressure detection sensor connected to the circuit board, which being configured to detect a pressure change signal on the apparatus shell.
Absstract of: US2025098991A1
Provided is a body-attachable unit configured to be attached to and inserted into a body for measuring biometric information, the body-attachable unit including a housing formed so that a bottom surface is configured to be attached to skin, a printed circuit board (PCB) substrate, which is disposed in the housing, with a plurality of electrical contacts formed to protrude from a surface of the PCB substrate, and a sensor member including a sensor body part disposed in the housing and a sensor probe part formed and extended from a side of the sensor body part to protrude outward from the bottom surface of the housing and configured to be inserted into the skin if the housing is attached to the skin, and at least one of the plurality of electrical contacts is formed to make contact with the sensor body part to support the sensor body part, remaining of the plurality of electrical contacts are formed to be spaced apart from the sensor body part, and the sensor body part is to make contact with all of the plurality of electrical contacts by manipulation by a user.
Absstract of: US2025099678A1
Disclosed herein are methods for establishing communication protocols between wireless devices in infusion pump systems. Infusion pump systems can include a number of components capable of wireless communication with one or more other components including an infusion pump, a continuous glucose monitoring (CGM) system and a smartphone or other multi-purpose consumer electronic device. Communications among these devices can be coordinated to increase efficiency and conserve battery power.
Absstract of: EP4527292A1
Provided is a body-attachable unit configured to be attached to and inserted into a body for measuring biometric information, the body-attachable unit including a housing formed so that a bottom surface is configured to be attached to skin, a printed circuit board (PCB) substrate, which is disposed in the housing, with a plurality of electrical contacts formed to protrude from a surface of the PCB substrate, and a sensor member including a sensor body part disposed in the housing and a sensor probe part formed and extended from a side of the sensor body part to protrude outward from the bottom surface of the housing and configured to be inserted into the skin if the housing is attached to the skin, and at least one of the plurality of electrical contacts is formed to make contact with the sensor body part to support the sensor body part, remaining of the plurality of electrical contacts are formed to be spaced apart from the sensor body part, and the sensor body part is to make contact with all of the plurality of electrical contacts by manipulation by a user.
Absstract of: EP4527291A2
A method and a system for improving the accuracy of a continuous glucose monitoring sensor by estimating a CGM signal at a time t+PH using a value of CGM at time t, using a short-time glucose prediction horizon to estimate the value of a CGM signal at a time t+PH with a noise estimation algorithm.
Absstract of: AU2023271749A1
Disclosed are techniques, devices and computer products in which a processor is operable to access blood glucose measurement values and insulin data from a data memory. Based on the blood glucose measurement values the processor may be operable to identify high events that exceed an upper target blood glucose set point and low events in which blood glucose measurement values are below a lower target blood glucose set point. Rules may be applied to the high events and low events. Based on a result of the rules, high event patterns may be identified as well as a low event pattern. A respective pattern weight may be applied to each identified high event and each identified low and a graphical user interface may be populated with a number of high event patterns and for a number of low event patterns.
Absstract of: US2023301557A1
Embodiments of the present disclosure relate to systems, devices and methods for continuous glucose monitoring. In some embodiments, a continuous glucose monitoring (CGM) device is provided that includes a subcutaneous implantable electrochemical sensing probe (sensor). The sensor is planar and comprises counter and working electrodes that are deposited at both sides of the sensing probe. A biocompatible layer deposited at the entire sensor circumference minimizes inflammatory reaction. A reel to reel production process provides “per sensor” layers' deposition at predefined spots on a base sheet during displacement between production stations. Production processes are conducted initially at one side of the base sheet followed by production processes on the opposite side. Sensor by sensor working electrode surface areas and layers' thickness are measured and “per sensor” data (“dry” parameters) is stored according to base sheet identifiers that could be implemented by printed or etched markings or else by other means such as RFID. In addition, batch parameters are measured on a sample basis (in vitro “wet” parameters). A factory calibration algorithm analyzes “per lot” sample of sensors' performance (in vitro “wet” parameters in glucose solutions) as well as individual sensor measurement and combines the data in a calibration algorithm to calculate individual sensor calibration parameters and data is programmed back to the individual sensor.
Nº publicación: ES3008659T3 24/03/2025
Applicant:
BBI MEDICAL INNOVATIONS LLC
BBI Medical Innovations, LLC
Absstract of: EP4464242A2
The present disclosure provides apparatuses and methods for measuring capacitance as an indication of susceptibility to the formation of a diabetic foot ulcer.
BOPI
Electronic site
